Posted by Michael Wonder on 11 Jan 2024
Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype
10 January 2024 - Approval based on a separate Phase 3 trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
GSK today announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.
